SFT 4003

**SFT 4003** is an investigational inhaled drug candidate being developed by invoX Pharma for **chronic obstructive pulmonary disease**. The company’s pipeline identified the program as Phase 1; however, no public information was identified that discloses its active ingredient, molecular modality, pharmacological target, or mechanism of action. invoX’s inhalation-development platform, Softhaler®, is a propellant-free soft-mist system intended to deliver liquid formulations to the lung, but the exact SFT 4003 formulation-device configuration has not been publicly specified. ([invoxpharma.com](https://invoxpharma.com/pipeline/))